Graham Walker, MD
Emergency Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Walker’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A115729 · Current
Licensed to practise in California · since 2011 · expires 2028-08-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Emergency Medicine - Emergency Medicine
- American Board of Preventive Medicine - Clinical Informatics
Drugs they prescribed that Part D paid
$1,408
Pharmacies billed $1,408 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 15% of their Part D prescriptions (14 of 95) in 2024. Above the middle of the specialty; the typical emergency medicine clinician is at 12%.
88 generic and fewer than 11 brand-name prescriptions · $1,408 in drug cost · 21 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ibuprofen | 14 | $105 | $8 |
| Oxycodone | 11 | $62 | $6 |
Year by year
| 2024 | 95 | 76 | 15% (14) | None | $1,408 |
| 2023 | 103 | 71 | 17% (17) | None | $7,261 |
| 2022 | 84 | 54 | 19% (16) | None | $1,334 |
| 2021 | 89 | 66 | 27% (24) | None | $1,936 |
| 2020 | 64 | 48 | None | 23% | $3,467 |
| 2019 | 80 | 60 | 16% (13) | None | $2,432 |
| 2018 | 97 | 67 | 12% (12) | 18% | $6,261 |
| 2017 | 79 | 61 | 14% (11) | 14% | $1,838 |
| 2016 | 128 | 94 | 27% (35) | None | $2,626 |
| 2015 | 166 | 120 | 22% (36) | None | $3,221 |
| 2014 | 159 | 114 | 24% (38) | 10% | $2,724 |
| 2013 | 131 | 89 | 28% (37) | None | $3,004 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Hydrocodone-Acetaminophen | 13 | $84 | $6 |
2021: 1 drug
| Hydrocodone-Acetaminophen | 18 | $120 | $7 |
2019: 1 drug
| Hydrocodone-Acetaminophen | 11 | $70 | $6 |
2016: 3 drugs
| Hydrocodone-Acetaminophen | 30 | $384 | $13 |
| Cephalexin | 12 | $124 | $10 |
| Ibuprofen | 11 | $107 | $10 |
2015: 2 drugs
| Hydrocodone-Acetaminophen | 20 | $241 | $12 |
| Cephalexin | 20 | $187 | $9 |
2014: 4 drugs
| Hydrocodone-Acetaminophen | 30 | $263 | $9 |
| Prednisone | 11 | $176 | $16 |
| Ondansetron Odt | 12 | $154 | $13 |
| Cephalexin | 11 | $107 | $10 |
2013: 3 drugs
| Hydrocodone-Acetaminophen | 21 | $179 | $9 |
| Ondansetron Odt | 12 | $159 | $13 |
| Ibuprofen | 12 | $88 | $7 |
Money from drug and device companies
$308,707 in 2025
| 2025 | 1 | 14 | $308,707 | $308,707 |
| 2024 | 1 | 1 | None | $70 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Xolair | $308,707 | 14 payments
|
See all 14 published payments
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-10-21 | Cosentyx | $23,485 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-09-08 | Cosentyx | $23,485 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-09-08 | Fabhalta | $20,500 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-05-28 | Kesimpta | $37,820 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-05-28 | Leqvio | $16,667 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Xolair | $19,375 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Xolair | $19,375 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Vanrafia | $23,500 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Vanrafia | $23,500 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Xolair | $19,375 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Xolair | $19,375 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Vanrafia | $23,500 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Xolair | $19,375 |
| Novartis Pharmaceuticals | Paid to speak or teach · 2025-04-18 | Xolair | $19,375 |
See earlier years (2024)
2024: $70
| Aidoc Medical | Briefcase | $70 | 1 payment
|
Professional record
- NPI
- 1093951949
- Licence
- CA A115729California A115729: Current · expires 2028-08-31
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207P00000X (207P00000X)
- Mailing address
- 300 Pasteur Dr, Mc: 5500, Stanford, CA, 94305
- NPI first listed
- 2008-12-24
- NPI last updated
- 2022-02-11
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.